Breakout Labs-backed Pareto names new CTO

Pareto Biotechnologies has hired Michael Mendez as its chief technology officer. Based in San Francisco, Pareto, which is backed by Breakout Labs, is a developer of a synthetic biology platform.

PRESS RELEASE

San Francisco, CA (February 4, 2014) – Pareto Biotechnologies announced today its appointment of Michael Mendez as its Chief Technology Officer (CTO).
“Synthetic biology needs a win, and Pareto’s novel platform has the ability to deliver,” said Mendez. “Our CEO, Jamie Bacher, has assembled the tools and the team required to take synthetic biology and apply not only an innovative platform, but produce quick-to-market products. I am excited to be a part of the team that will lead the next molecular revolution.” Over the course of his career, Mendez has successfully transitioned groundbreaking scientific discoveries into nine startups, four of which he co-founded, most recently Sapphire Energy.
Mendez will head Pareto’s scientific efforts in San Diego, to further develop and expand applicability of the company’s technology. Pareto’s platform is unique, in that it enables the production of “designer molecules,” significantly enhanced and naturally derived high-value molecules, which will allow the company to capture large shares of existing markets. The company holds significant intellectual property, enabling Pareto dominant use and applicability of its platform to various markets, from cosmetics, flavors and fragrances in the near term, to commodities and therapeutics in the long term.
“Pareto has recruited a true veteran to lead a molecular revolution in our industry,” said Pareto’s CEO, Jamie Bacher. “Mike Mendez has an exceptional understanding of the development of novel platforms, as evidenced in his past success developing the mouse with a humanized immune system, creating cancer vaccines, and leveraging the power of algae for biofuels. Pareto is well positioned to further its leading role in defining the future of synthetic biology, marrying its emerging technology with a strategy to develop quick-to-market products that can bridge a gap to long term products with high social and economic value.”
About Pareto Biotechnologies:
Pareto Biotechnologies has pioneered development of a revolutionary synthetic biology platform that produces naturally derived, high value “designer molecules. Pareto’s technology is the result of over a decade of academic and private sector research and intellectual property focused on the polyketide pathway. Building on Dr. Joe Noel’s groundbreaking research at the Salk Institute, and previously dismissed as the “poor man’s pathway,” Pareto’s platform is capable of generating known products and novel molecules. In the near term, Pareto will introduce “designer molecules” as cosmetics, flavors and fragrances with enhanced and novel qualities. In the long term, Pareto’s molecules will be designed to enhance therapeutics and industrial commodities.

 

Related Posts

Leave a Reply

PEHUB Community

Join the 12503 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget